2 Carlson LA, OlssonAG. Intravenous prostaglandin E1 in severe peripheral vascular disease[J].Lancet, 1976, 9(7886)∶810 被引量：1
3 Shindo H,Tawata M,Inoue M,et al.The effect of prostaglandin E1 alphaCD on vibratory threshold determined with the SMV-5 vibrometer in patients with diabeticneuropathy[J].Diabetes Res Clin Pract, 1994, 24(3)∶173～180 被引量：1
5 Toyota T, Hirata Y, Ikeda Y, et al. Lipo-PGE1, a newlipid-encapsulated preparation of prostaglandin E1：placebo-and prostaglandinE1-controlled multicenter trials in patients with diabetic neuropathy and legulcers[J]. Prostaglandins, 1993, 46(5)∶453～468 被引量：1
6 Mizushima Y, Yanagawa A, Hoshi K, et al. prostaglandin E1 is more effective,when incorporated in lipid microspheres, for treatment of peripheral vascular disease inman[J].J Pharm Pharmacol, 1983, 35(3)∶666～667
收稿：2000-02-24修回：2000-05-08 被引量：1
7Axelrod L.Insulin.Prostaglandins and the pathogenesis of hypertension.diabetes 1991; 40:1223-1226. 被引量：1
9Toyota T,Hirata Y,Iketa Y,et al,Lipo PGE1,a new lipidencapsulatd preparation of prostaglandin El,:placebo and prostaglandin El,-conctrolled multicenter trials in patients with diabetic neuropathy and leg ulcers[J]. 被引量：1
10Saeki S,Yamamura K,Matsushita M,et al.Iontophoretic application of prostaglandin El for improvement in peripheral microcirculation.Int J Clin Pharmacol Ther 1998; 6:529.prostaglandins 1993,46 (5):453-468. 被引量：1
